• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconAstraZeneca

AstraZeneca

A robot arm from ABB on display at Automatica 2023 in Munich. (Photo: Sven Hoppe/dpa/Getty Images)
NewslettersSoftBank will acquire ABB’s robotics business
By Andrew NuscaOctober 9, 2025
PoliticsAstraZeneca begins European exit—will invest $50 billion in the U.S. amid tariff threats
By AFPJuly 22, 2025
PoliticsU.K. business leaders are ‘struggling to see what’s business-friendly’ about Labour
By Jamie Nimmo, Irina Anghel, Jennifer Creery and BloombergJuly 7, 2025
EconomyNew London IPOs hit 28-year low amid AstraZeneca exit concerns
By Pablo Mayo Cerqueiro, Joe Easton, Neil Campling and BloombergJuly 3, 2025
FinanceAstraZeneca CEO hopes U.S. will represent half of company’s global revenue by 2030—vows to invest and expand in nation despite tariff threat
By AFPApril 29, 2025
TechAstraZeneca to buy cell therapy biotech for up to $1 billion
By Ashleigh Furlong and BloombergMarch 17, 2025
HealthAstraZeneca sees profits surge despite Chinese import tax allegations
By AFPFebruary 6, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
HealthHate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Ryanair ceo Michael O'Leary sitting by a table
SuccessRyanair’s Michael O’Leary, who is up for a $108 million bonus, doesn’t see high CEO pay as a problem: ‘Footballers are getting half a million a week’
By Prarthana PrakashJanuary 10, 2025
Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.
HealthMerck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
By Lindsey LeakeDecember 20, 2024
RetailAstraZeneca says it’s taking China’s investigations into fraud, illegal drug importation and data collection ‘very seriously’
By AFPNovember 12, 2024
LeadershipAstraZeneca’s China chief detained in illegal data collection and drug import probe, pharma giant says
By AFPNovember 7, 2024
FinanceAstraZeneca’s drive for China dominance in focus as chief probed
By Amber Tong and BloombergOctober 31, 2024
Pascal Soriot, chief executive officer of AstraZeneca Plc.
RetailAstraZeneca sets bold revenue target as CEO aims to double sales to $80 billion by 2030
By Ashleigh Furlong and BloombergMay 21, 2024
HealthAstraZeneca pulls its COVID-19 vaccine from European market after history of stumbles
By The Associated PressMay 9, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...13
Most Popular
Economy
Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House postAn image of a popular article
By Eleanor PringleFebruary 4, 2026
Success
In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’An image of a popular article
By Emma BurleighFebruary 2, 2026
Investing
Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the boardAn image of a popular article
By Jim EdwardsFebruary 4, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.